Allison Transmission heads into the back half of May with the stock under pressure after a disappointing earnings reaction — yet the analyst community is quietly marking up targets rather than stepping away.
The tension is sharp. Q1 results landed on May 4 and the stock fell roughly 3% the next day, then lost another 6% over five sessions. Including a 3.2% drop on Tuesday, ALSN is now down nearly 7% over the past month to $119.80. The earnings move was modest by historical standards but the drift since has been persistent — the stock closed through the $120 level with little sign of buyers stepping in.
That weakness sits awkwardly against the analyst response. Morgan Stanley raised its target to $126 from $117 this week, maintaining its Equal-Weight rating. That follows Wells Fargo lifting to $137 from $127 last week, also on a neutral stance. The message from both firms is consistent: estimates are nudging higher, but neither is ready to call a re-rating. The mean Street target is $137.40 — a 15% premium to the current price. That gap looks wide for a stock where most active coverage remains at neutral or hold. Oppenheimer is the outlier with an Outperform rating and a $135 target. The overall setup reads as a market that respects the fundamentals but isn't rushing to buy the dip.
Valuation offers some support for the cautious optimism. The EV/EBITDA multiple has compressed to around 7.4x, down roughly 0.3x over the past month as the stock has slid. The P/E has contracted similarly, dropping nearly 1.6 turns over 30 days. At current levels these multiples are not demanding for a well-run industrial franchise with stable margins. The EV/EBIT factor score ranks in the 81st percentile, suggesting the earnings yield is tracking well above peers on a relative basis. EPS momentum over 30 days is solid at the 77th percentile, even if the 90-day read is softer at the 22nd — pointing to recent estimate upgrades following a period of relative stagnation.
Short interest is not the story here, but it does add a layer of context. Short interest has climbed about 28% over the past month, moving from roughly 2.0% to 3.1% of the free float — a noticeable build, but still a level that reflects measured skepticism rather than crowded conviction. Borrow conditions are extremely loose. The cost to borrow is just 0.40% annualised, and availability is very wide — lending conditions offer no friction to new shorts building positions if they choose. The ORTEX short score of 34.8 sits in the lower half of its range, and the options put/call ratio of 0.80 is almost exactly in line with its 20-day average. Neither the lending market nor the options market is flashing urgency in either direction.
The insider register is similarly low-key. CFO Scott Mell sold approximately $284,000 worth of stock on May 8, split across two transactions at $125. Those trades follow a smaller $113,000 sell in April. The selling is modest in absolute terms and carries low significance scores, consistent with routine plan-based activity rather than a signal about near-term confidence. Net insider activity over 90 days shows a small positive net in share terms once awards are included, but cash-value selling slightly dominates open-market transactions. Among institutional holders, FMR (Fidelity) remains the largest position at 12.4% of shares and added 110,000 shares to the end of April. Boston Partners added 540,000 shares through March, making it one of the more active accumulators in the shareholder base.
The next earnings event is not due until July 24, leaving roughly ten weeks of price discovery without a fundamental catalyst. Close peer MTW fell 6% on the week — roughly in line with ALSN — while WAB managed a 2% gain and PCAR was nearly flat, suggesting the selling in ALSN is at least partly idiosyncratic rather than a pure sector flush. What to watch through the summer: whether the gap between the consensus target and the current price draws incremental buyers, or whether the post-earnings drift continues to pressure a stock that the Street nominally likes but isn't aggressively defending.
See the live data behind this article on ORTEX.
Open ALSN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
